What's Happening?
Dynamic42 and Experimental Pharmacology and Oncology (EPO), both based in Germany, have announced a strategic collaboration to enhance preclinical models in brain cancer research. This partnership focuses on integrating organ-on-chip technologies into
the core of preclinical drug development. By combining Dynamic42's organ-on-chip platforms with EPO's expertise in translational oncology, the collaboration aims to develop experimental setups that more accurately reflect human tumor biology. The initial projects target glioblastoma and the blood-brain barrier, utilizing Dynamic42's human-based BBB-on-chip model to explore therapeutic responses. This approach seeks to improve the reliability of data translation into clinical outcomes.
Why It's Important?
The integration of organ-on-chip technology into preclinical research represents a significant advancement in the field of oncology. By providing more human-relevant models, this collaboration addresses a critical gap in drug development, where decisions often rely on data that may not fully reflect human biology. The use of these advanced in vitro systems can enhance the understanding of tumor biology, improve decision-making, and reduce the risk of late-stage failures in drug development. This initiative supports the ongoing shift towards more targeted, biology-driven research strategies, aligning with the principles of the 3Rs (Replace, Reduce, Refine) in scientific research.
What's Next?
Dynamic42 and EPO plan to present the initial results of their collaboration at the American Association for Cancer Research Annual Meeting 2026. The partnership is expected to expand further, exploring additional indications and extending the use of organ-on-chip technologies across various areas of drug development. This expansion will likely involve continued collaboration between early-career researchers from both organizations, fostering scientific exchange and innovation. The success of this initiative could pave the way for broader adoption of organ-on-chip technologies in preclinical research, potentially transforming the landscape of drug development.
